Phase I Trial of a Lactobacillus Crispatus Vaginal Suppository for Prevention of Recurrent Urinary Tract Infection in Women

Overview

Journal Infect Dis Obstet Gynecol

Publisher Wiley

Specialties Gynecology & Obstetrics
Infectious Diseases

Date 2008 Feb 22

PMID 18288237

Citations 28

Authors

Christopher A Czaja

Ann E Stapleton

Yuliya Yarova-Yarovaya

Walter E Stamm

Affiliations

Soon will be listed here.

Abstract

Objectives: We performed a phase I trial to assess the safety and tolerance of a Lactobacillus vaginal suppository for prevention of recurrent UTI.

Methods: Premenopausal women with a history of recurrent UTI were randomized to use L. crispatus CTV-05 or placebo vaginal suppositories daily for five days.

Results: 30 women were randomized (15 to L. crispatus CTV-05). No severe adverse events occurred. Mild to moderate vaginal discharge and genital irritation were reported by women in both study arms. Seven women randomized to L. crispatus CTV-05 developed pyuria without associated symptoms. Most women had high concentrations of vaginal H202-producing lactobacilli before randomization. L. crispatus, L. jensenii, and L. gasseri were the most common Lactobacillus species identified, with stable prevalence over time.

Conclusions: L. crispatus CTV-05 can be given as a vaginal suppository with minimal sideeffects to healthy women with a history of recurrent UTI. Mild inflammation of the urinary tract was noted in some women.

Citing Articles

Probiotic significance of strains: a comprehensive review on health impacts, research gaps, and future prospects.

Shah A, Baiseitova A, Zahoor M, Ahmad I, Ikram M, Bakhsh A Gut Microbes. 2024; 16(1):2431643.

PMID: 39582101 PMC: 11591481. DOI: 10.1080/19490976.2024.2431643.

Can vaginal lactobacillus suppositories help reduce urinary tract infections?.

Shoureshi P, Niino C, Eilber K Int Urogynecol J. 2023; 34(11):2713-2718.

PMID: 37392226 PMC: 10682044. DOI: 10.1007/s00192-023-05568-4.

Lactobacillus crispatus-loaded electrospun fibers yield viable and metabolically active bacteria that kill Gardnerella in vitro.

Mahmoud M, Wesley M, Kyser A, Lewis W, Lewis A, Steinbach-Rankins J Eur J Pharm Biopharm. 2023; 187:68-75.

PMID: 37086869 PMC: 10192109. DOI: 10.1016/j.ejpb.2023.04.011.

The right bug in the right place: opportunities for bacterial vaginosis treatment.

Wu S, Hugerth L, Schuppe-Koistinen I, Du J NPJ Biofilms Microbiomes. 2022; 8(1):34.

PMID: 35501321 PMC: 9061781. DOI: 10.1038/s41522-022-00295-y.

Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis.

Abdullatif V, Sur R, Eshaghian E, Gaura K, Goldman B, Panchatsharam P Cureus. 2021; 13(10):e18843.

PMID: 34671514 PMC: 8523083. DOI: 10.7759/cureus.18843.

References

Andreu A, Stapleton A, Fennell C, Hillier S, Stamm W . Hemagglutination, adherence, and surface properties of vaginal Lactobacillus species. J Infect Dis. 1995; 171(5):1237-43. DOI: 10.1093/infdis/171.5.1237. View

Reid G, Bruce A, Taylor M . Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections. Clin Ther. 1992; 14(1):11-6. View

Gupta K, Scholes D, Stamm W . Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999; 281(8):736-8. DOI: 10.1001/jama.281.8.736. View

Hooton T, Hillier S, JOHNSON C, Roberts P, Stamm W . Escherichia coli bacteriuria and contraceptive method. JAMA. 1991; 265(1):64-9. View

Burton J, Cadieux P, Reid G . Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. Appl Environ Microbiol. 2003; 69(1):97-101. PMC: 152440. DOI: 10.1128/AEM.69.1.97-101.2003. View

Osset J, Bartolome R, Garcia E, Andreu A . Assessment of the capacity of Lactobacillus to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. J Infect Dis. 2001; 183(3):485-91. DOI: 10.1086/318070. View

Cadieux P, Burton J, Gardiner G, Braunstein I, Bruce A, Kang C . Lactobacillus strains and vaginal ecology. JAMA. 2002; 287(15):1940-1. DOI: 10.1001/jama.287.15.1940. View

Marrazzo J, Cook R, Wiesenfeld H, Murray P, Busse B, Krohn M . Women's satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis. J Womens Health (Larchmt). 2006; 15(9):1053-60. DOI: 10.1089/jwh.2006.15.1053. View

Gupta K, Stapleton A, Hooton T, Roberts P, Fennell C, Stamm W . Inverse association of H2O2-producing lactobacilli and vaginal Escherichia coli colonization in women with recurrent urinary tract infections. J Infect Dis. 1998; 178(2):446-50. DOI: 10.1086/515635. View

10.

Hooton T, Roberts P, Stamm W . Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis. 1994; 19(2):274-8. DOI: 10.1093/clinids/19.2.274. View

11.

Hawes S, Hillier S, Benedetti J, Stevens C, Koutsky L, Wolner-Hanssen P . Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections. J Infect Dis. 1996; 174(5):1058-63. DOI: 10.1093/infdis/174.5.1058. View

12.

Reid G, Charbonneau D, Erb J, Kochanowski B, Beuerman D, Poehner R . Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol. 2003; 35(2):131-4. DOI: 10.1016/S0928-8244(02)00465-0. View

13.

Vasquez A, Jakobsson T, Ahrne S, Forsum U, Molin G . Vaginal lactobacillus flora of healthy Swedish women. J Clin Microbiol. 2002; 40(8):2746-9. PMC: 120688. DOI: 10.1128/JCM.40.8.2746-2749.2002. View

14.

Antonio M, Hillier S . DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol. 2003; 41(5):1881-7. PMC: 154705. DOI: 10.1128/JCM.41.5.1881-1887.2003. View

15.

Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H . A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents. 2006; 28 Suppl 1:S30-4. DOI: 10.1016/j.ijantimicag.2006.05.008. View

16.

Reid G, Bruce A, Fraser N, Heinemann C, Owen J, Henning B . Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol. 2001; 30(1):49-52. DOI: 10.1111/j.1574-695X.2001.tb01549.x. View

17.

Valore E, Wiley D, Ganz T . Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun. 2006; 74(10):5693-702. PMC: 1594936. DOI: 10.1128/IAI.00524-06. View

18.

Stamm W, Hooton T . Management of urinary tract infections in adults. N Engl J Med. 1993; 329(18):1328-34. DOI: 10.1056/NEJM199310283291808. View

19.

Stamm W, Wagner K, Amsel R, ALEXANDER E, Turck M, COUNTS G . Causes of the acute urethral syndrome in women. N Engl J Med. 1980; 303(8):409-15. DOI: 10.1056/NEJM198008213030801. View

20.

Foxman B, Barlow R, DArcy H, Gillespie B, Sobel J . Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000; 10(8):509-15. DOI: 10.1016/s1047-2797(00)00072-7. View